Drug intelligence / Profile preview

Methoxamine

Development stage: Phase 2
Lead developer: Norgine
Modality: Small Molecules
Administration: Perianal, Intraanal, Intrarectal, Rectal, Intramuscular, Intravenous

Overview

Methoxamine is a small molecule that functions as a selective alpha-1 adrenergic receptor agonist. It is being investigated for its effects on mean anal resting pressure, as well as for its use as a vasopressor to prevent and treat hypotension in various surgical settings, including during spinal anesthesia for cesarean deliveries and carotid endarterectomy. Additionally, its potential role in conditions like tourniquet shock, myocardial injury, gastrointestinal neoplasms, postoperative cognitive dysfunction, and gastric cancer is under exploration. Early research also suggests its involvement in central alpha-1 adrenoceptor activity related to narcolepsy.

Brand names: VasoxylVasoxineVasylox
Other names: 甲氧明Methoxamedrine

Targets

ADRA1A (α1A)

Beyond the preview

Go deeper on Methoxamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Methoxamine.

Explore the full profile